William Damsky1, Durga Thakral2, Meaghan K McGeary3, Jonathan Leventhal2, Anjela Galan2, Brett King4. 1. Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: william.damsky@yale.edu. 2. Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. 3. Department of Pathology, Yale School of Medicine, New Haven, Connecticut. 4. Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.king@yale.edu.
Abstract
BACKGROUND: Sarcoidosis and granuloma annulare (GA) are cutaneous granulomatous disorders that can be difficult to treat. There is evidence of underlying Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway activation in sarcoidosis, suggesting that JAK inhibition might be effective. OBJECTIVE: To evaluate treatment with tofacitinib, a JAK inhibitor, in patients with recalcitrant sarcoidosis and GA. METHODS: A prospective evaluation of tofacitinib in 4 consecutive patients with recalcitrant cutaneous sarcoidosis (n = 3) and generalized GA (n = 1) was conducted. Immunohistochemical analysis of skin biopsy specimens from other patients with sarcoidosis (n = 21) and GA (n = 17) was performed to characterize patterns of JAK-STAT pathway activation. RESULTS: Tofacitinib resulted in a mean improvement in the baseline Cutaneous Sarcoidosis Activity and Morphology Instrument and Granuloma Annulare Scoring Index scores of 96% (standard deviation, 2%). Histologic resolution of disease was documented in all patients (3 out of 3) who had skin biopsies while receiving therapy. Constitutive STAT1 and STAT3 activation was observed in both sarcoidosis and GA, albeit in different patterns. Signal regulatory protein α may explain the differences in JAK-STAT signaling between sarcoidosis and GA. LIMITATIONS: The study is limited by the small number of participants. CONCLUSIONS: Tofacitinib resulted in dramatic improvement in 4 patients with cutaneous sarcoidosis and GA. Larger studies are underway to better understand this effect.
BACKGROUND:Sarcoidosis and granuloma annulare (GA) are cutaneous granulomatous disorders that can be difficult to treat. There is evidence of underlying Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway activation in sarcoidosis, suggesting that JAK inhibition might be effective. OBJECTIVE: To evaluate treatment with tofacitinib, a JAK inhibitor, in patients with recalcitrant sarcoidosis and GA. METHODS: A prospective evaluation of tofacitinib in 4 consecutive patients with recalcitrant cutaneous sarcoidosis (n = 3) and generalized GA (n = 1) was conducted. Immunohistochemical analysis of skin biopsy specimens from other patients with sarcoidosis (n = 21) and GA (n = 17) was performed to characterize patterns of JAK-STAT pathway activation. RESULTS:Tofacitinib resulted in a mean improvement in the baseline Cutaneous Sarcoidosis Activity and Morphology Instrument and Granuloma Annulare Scoring Index scores of 96% (standard deviation, 2%). Histologic resolution of disease was documented in all patients (3 out of 3) who had skin biopsies while receiving therapy. Constitutive STAT1 and STAT3 activation was observed in both sarcoidosis and GA, albeit in different patterns. Signal regulatory protein α may explain the differences in JAK-STAT signaling between sarcoidosis and GA. LIMITATIONS: The study is limited by the small number of participants. CONCLUSIONS:Tofacitinib resulted in dramatic improvement in 4 patients with cutaneous sarcoidosis and GA. Larger studies are underway to better understand this effect.
Authors: George P Christophi; Tiffany Caza; Christopher Curtiss; Divya Gumber; Paul T Massa; Steve K Landas Journal: Exp Mol Pathol Date: 2014-04-21 Impact factor: 3.362
Authors: James T Rosenbaum; Sirichai Pasadhika; Elliott D Crouser; Dongseok Choi; Christina A Harrington; Jinnell A Lewis; Carrie R Austin; Tessa N Diebel; Emily E Vance; Rita M Braziel; Justine R Smith; Stephen R Planck Journal: Clin Immunol Date: 2009-05-22 Impact factor: 3.969
Authors: Tong Zhou; Wei Zhang; Nadera J Sweiss; Edward S Chen; David R Moller; Kenneth S Knox; Shwu-Fan Ma; Michael S Wade; Imre Noth; Roberto F Machado; Joe G N Garcia Journal: PLoS One Date: 2012-09-12 Impact factor: 3.240
Authors: Marcia A Friedman; Brian Le; Janelle Stevens; Julianna Desmarais; Daniel Seifer; Kimberly Ogle; Dongseok Choi; Christina A Harrington; Peter Jackson; James T Rosenbaum Journal: Lung Date: 2021-04-07 Impact factor: 2.584
Authors: Nevin Hammam; Michael Evans; Esi Morgan; Andreas Reimold; Christine Anastasiou; Julia L Kay; Jinoos Yazdany; Gabriela Schmajuk Journal: Arthritis Care Res (Hoboken) Date: 2022-01-28 Impact factor: 4.794
Authors: Carmen Álvarez-Reguera; Diana Prieto-Peña; Alba Herrero-Morant; Lara Sánchez-Bilbao; José Luis Martín-Varillas; Elena González-López; María Gutiérrez-Larrañaga; David San Segundo; Rosalía Demetrio-Pablo; Gonzalo Ocejo-Vinyals; Miguel A González-Gay; Ricardo Blanco Journal: Ther Adv Musculoskelet Dis Date: 2022-04-29 Impact factor: 3.625